<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416390</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000492778</org_study_id>
    <secondary_id>UIC-1999-0489</secondary_id>
    <nct_id>NCT00416390</nct_id>
  </id_info>
  <brief_title>Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia</brief_title>
  <official_title>The Effect of Lycopene on DNA Damage in Human Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain substances to keep cancer from forming,&#xD;
      growing, or coming back. Eating a diet high in lycopene, a substance found in tomatoes and&#xD;
      tomato products, may keep cancer from forming or growing. Collecting and storing samples of&#xD;
      blood from patients with cancer to study in the laboratory may help doctors learn more about&#xD;
      changes that may occur in DNA and identify biomarkers related to cancer.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying how well lycopene works in treating&#xD;
      patients with prostate cancer or benign prostatic hyperplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the ability of prostatic tissue to accumulate doses of lycopene in patients with&#xD;
           prostate cancer or benign prostate hyperplasia.&#xD;
&#xD;
        -  Determine whether the steady state level of DNA oxidation in blood and prostate tissue&#xD;
           is responsive to lycopene dosing.&#xD;
&#xD;
        -  Investigate the effect of lycopene dosing on the lipid peroxidation marker&#xD;
           malondialdehyde in serum.&#xD;
&#xD;
        -  Assess the importance of measuring multiple DNA oxidation products as biomarkers of&#xD;
           oxidative stress and its chemoprevention.&#xD;
&#xD;
        -  Determine the significance of DNA oxidation products in blood as an indicator of&#xD;
           oxidative stress in the prostate.&#xD;
&#xD;
        -  Measure prostate and blood uptake of the chemoprevention agent lycopene.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral lycopene once daily for 3 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo once daily for 3 weeks. In both arms, patients&#xD;
           undergo biopsy to confirm diagnosis of prostate cancer or benign prostatic hyperplasia&#xD;
           after 3 weeks of study therapy.&#xD;
&#xD;
      Blood samples are collected at baseline and before surgery for biomarker/laboratory studies.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">March 2011</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of prostatic tissue to accumulate doses of lycopene</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Responsiveness of steady state level of DNA oxidation in blood and prostate tissue to lycopene dosing</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of lycopene on lipid peroxidation marker malondialdehyde in serum</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Importance of measuring multiple DNA oxidation products as biomarkers of oxidative stress and its chemoprevention</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Significance of DNA oxidation products in blood as an indicator of oxidative stress in the prostate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate and blood uptake of the chemoprevention agent lycopene</measure>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Nonmalignant Neoplasm</condition>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lycopene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Prostate cancer&#xD;
&#xD;
               -  Benign prostate hyperplasia&#xD;
&#xD;
          -  High blood levels of prostate-specific antigen&#xD;
&#xD;
          -  Enlarged prostate&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard B. van Breemen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>benign prostatic hyperplasia</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lycopene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

